Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, global, open label study which includes a Phase 1b evaluation of
elacestrant in combination with abemaciclib in women and men with with or without brain
metastases from ER positive, HER-2 negative breast cancer. Phase 1b is designed to select the
recommended phase 2 dose and will be followed by a randomized Phase 2 evaluation of
elacestrant alone or in combination with abemaciclib in women and men with brain metastases
from ER positive, HER-2 negative breast cancer.